These passed my way today and look interesting, especially the SwanBio one:
swanbiotx.com/investors-and...
I am not sure the second one means much other than that the FDA in America has accepted AMN Fast Track Designation for AMN.
newcontact.eu/secure/media/...
The other interesting fact I picked up is that the latter suggests that the incidence of AMN is 1 in 10,000, not the 1 in 20,000 usually quoted. This might mean (in theory) that AMN is twice as likely than before to be the subject of drug development.